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Abstract Vascular endothelial cells respond to cytokines uch 
as IL-I[~ or TNF-ct by undergoing a number of functional 
alterations. Among these alterations is the induction of cell 
surface adhesion molecules, including VCAM-I. In this report, 
we investigated the effects of a 3-alkoxybenzo[~]thiophene-2- 
carboxamide (BZT) on the cytokine induction of VCAM-1 
expression and activation of the transcription factor NF-rB in 
human endothelial cells. BZT blocked the IL-I~ induced cell 
surface expression of VCAM-I in human endothelial cells but did 
not prevent nuclear translocation of NF-r,B. This study 
demonstrates that BZT is a potent inhibitor of VCAM-1 
expression in human endothelial cells. 
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1. Introduction 
Vascular endothelial cells undergo a number of morpholog- 
ical and functional changes in response to cytokines. These 
changes include the increased synthesis and expression of spe- 
cific cell surface adhesion molecules including E-selectin, in- 
tercellular adhesion molecule-1 (ICAM-1), and vascular cell 
adhesion molecule-I (VCAM-1) (see [1] for review). At sites 
of inflammation, recruitment of  leukocytes is mediated by the 
interaction of distinct integrin receptors on the leukocytes 
with the cell surface adhesion molecules on the vascular en- 
dothelial cell. 
The intracellular signaling mechanisms by which these ad- 
hesion molecule genes are induced in response to cytokine 
stimulation are beginning to be elucidated. In particular, the 
induction of VCAM-1 in endothelial cells is directly due to 
increased transcription rather than mobilization of  intracellu- 
lar pools of protein [2,3]. Recently, the promoter region for 
VCAM-1 was shown to contain two decameric sequences that 
are recognized by the nuclear factor ~cB (NF-~B)/Rel family of 
transcription factors [4,5]. These ~B sites are required for in- 
duction of VCAM-1 gene transcription [4,5]. 
NF-~cB is normally found in the cytosol of most cell types 
as an inactive heterodimer bound to an inhibitor protein, 
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DcBct [6-12]. The I~cBtx protein is rapidly phosphorylated 
and subsequently degraded upon stimulation with cytokines 
such as interleukin-ll3 (IL-113) and tumor necrosis factor-~ 
(TNF-ct) [13-17]. This allows NF-~cB to translocate to the 
nucleus and modulate gene expression. 
Recently, Boschelli et al. [18] described compounds based 
on the structure of a 3-alkoxybenzo[13]thiophene-2-carboxa- 
mide that blocked the adhesion of neutrophils to endothelial 
cells. In the present report, we investigated the mechanism of 
action of a 3-alkoxybenzo[13]thiophene-2-carboxamide (BZT) 
using human endothelial cells. We demonstrated that BZT 
inhibited the IL-113 induced cell surface expression and pro- 
moter activity of VCAM-1 in human endothelial cells. In ad- 
dition, we show that BZT does not affect IL-113 induced nu- 
clear translocation of NF-~cB. Therefore, it appears that IL-113 
stimulated translocation of NF-~B is not sufficient for 
VCAM-1 gene expression in endothelial cells. 
2. Materials and methods 
2.1. Cells and cell culture 
Human umbilical vein endothelial cells (HUVEC) were purchased 
from Clonetics (San Diego, CA) and used between passages 2 and 6. 
The human endothelial cell line ECV304 was purchased from ATCC 
(Rockville, MD). HUVEC and ECV304 were grown in EGM media 
(Clonetics, San Diego, CA). 
2.2. Chemicals and reagents 
N-Tosyl-Phe-chloromethylketone (TPCK) was purchased from Sig- 
ma (St. Louis, MO). The 3-alkoxybenzo[13]thiopbene-2-carboxamide 
(BZT) was synthesized according to the procedures described by 
Boschelli et al. [18]. All DNA oligonucleotides were synthesized on 
an ABI 381A DNA synthesizer (Applied Biosystems, Foster City, 
CA). IL-I[3 was purchased from R&D Systems (Minneapolis, MN). 
Compounds were dissolved in DMSO (Sigma). 
2.3. ELISA 
HUVEC (-< passage 6) were plated on gelatin coated 96-well tissue 
culture dishes (CoStar, Cambridge, MA) and incubated at 37°C over- 
night. The cells were then pre-treated with the test compound for 30 
min followed by a 6 h incubation with the test compound and 0.5 ng/ 
ml IL-I~. Samples were run in triplicate and each experiment was 
performed a minimum of three times. Following the 6 h treatment, 
the HUVEC were washed once with PBS. Cells were then fixed by 
incubation in 3.7% formaldehyde/PBS for 5-10 min. Fixed HUVEC 
were stored at 4°C overnight in PBS containing 0.02% sodium azide. 
After the PBS/azide solution was aspirated, fixed cells were incubated 
in 1% BSA in PBS (dilution/wash buffer) for 1 h at 37°C. This solu- 
tion was then aspirated and replaced with anti VCAM-1 monoclonal 
antibody IG11B1 (Monosan, Uden, The Netherlands)diluted 1:1000. 
Plates were then incubated for 1-2 h at 37°C. The antibody solution 
was aspirated and the cells were subsequently washed 3 times with 
wash buffer. Wash buffer was replaced with a 1:5000 dilution of anti 
mouse IgG/horseradish peroxidase conjugate (Promega, Madison, 
WI) and then incubated at 37°C for 1 h, Conjugate solution was 
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aspirated and cells were washed 3 times. TMB/E substrate solution 
(Chemicon, Temecula, CA) was then applied to the cells. When ade- 
quate color had developed, an equal volume of 2 N sulfuric acid was 
added to stop the reaction. Spectrophotometric eadings at wave- 
length 450 nm were measured in a Molecular Devices (Menlo Park, 
CA) plate reader. 
2.4. Toxicity evaluation 
Test compounds at concentrations presented herein were shown to 
be non-toxic by the following procedure. Viability (< 80°/,, = toxic) of 
HUVEC treated with experimental compounds was determined using 
the alamarBlue assay (BioSource International, Camarillo, CA) ac- 
cording to the manufacturer's instructions. HUVEC were cultured 
in gelatin coated 96-well tissue culture dishes until confluent. Test 
compounds were evaluated in quadruplicate in EGM/10% alamarBlue 
reagent. Flourimeter readings (excitation, 530 nm; emission, 590 nm) 
were taken after a 6 h incubation. A visual inspection of the cells was 
also performed to ensure that no morphology changes had occurred. 
2.5. Reverse transcriptaselpolymerase chain reaction (RTIPCR) 
analyses 
All RT/PCR analyses were performed using the GeneAmp RNA/ 
PCR kit (Perkin Elmer, Branchburg, NJ). HUVEC, plated in gelatin 
coated T25 tissue culture flasks (Corning, Inc., Coming, NY), were 
treated in the same manner as described previously for the ELISA. 
Total RNA was isolated using RNAzol B following the procedures of 
the manufacturer (BioTecX, Houston, TX). Human 13-actin primer 
pairs generated a fragment of 838 base pairs and were purchased 
from Clontech (Palo Alto, CA). The thermal cycling parameters 
were as described by Clontech. The plasminogen activator inhibitor 
type 1 (PAl-l) primers amplified a product of 800 base pairs and 
contained the following sequences: 5'-CTACTTCAACGGCCAGTG- 
GAAGACTC-3', 5'-GAGGCCAAGGTCTTGGAGACAGATCT-3'. 
The PCR primers for human VCAM-1 amplified a product of ll01 
base pairs and contained the following sequences: 5'-TTACACATT- 
GATGAAATGGATTCTGT-3', 5'-AAGGTGAGAGTTGCATTCT- 
CAGAAAG-3'. The amplified PCR products were analyzed by elec- 
trophoresis n a 3% agarose gel (3:1 GTG NuSieve, FMC, Rockland, 
ME: Ultrapure agarose, Life Technologies, Gaithersburg, MD). 
2.6. LuciJerase assays 
Genomic DNA was isolated from HUVEC following the procedure 
of Cobb et al. [19]. The VCAM-1 promoter egion (1811 base pairs) 
was amplified following the procedures of the GeneAmp kit (Perkin 
Elmer, Norwalk, CT). The primers used to amplify the fragment were 
as follows: 5'-GGTACCGGCATTTCTCCAATGTTGCAAGCT-3' 
and 5'-GGTACCATAGTGGTTCCAAAACCCTTA-3'. The VCAM 
-1 promoter fragment (-1717 to +94 base pairs [4]) was cloned into 
the Kpnl site of pGL2 (Promega, Madison, WI). The neo gene was 
subcloned from pMAMneo (Clontech, Palo Alto, CA) into the Bum- 
HI site of pGL2VCAM-1 to generate pGLneoVCAM-I. Positive 
clones were identified by restriction digest and confirmed by DNA 
sequence analysis (Sequenase, US Biochemicals, Cleveland, OH). Plas- 
mid DNA was purified using standard procedures [20]. pGLneoV- 
CAM-1 DNA was then transfected into ECV304 cells using Lipofec- 
tin (Life Technologies, Gaithersburg, MD) and selected for resistance 
to geneticin (Life Technologies) at a concentration of 300 ~tg/ml. 
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Fig. 2. Inhibition of IL-I~ induced cell surface expression of 
VCAM-I. HUVEC were plated in gelatin coated 96-well plates and 
were treated with the indicated concentrations of BZT or TPCK for 
30 min prior to the addition of 0.5 ng/ml IL-I[3. Samples were then 
incubated for 6 h with IL-I~ and the test compound and then treat- 
ed as described. Samples were performed in triplicate. Results are 
given as mean+S.D. VCAM-I cell surface expression in HUVEC 
monolayers. No treatment OD4s0nm = 0.098 (S.D. = 0.061) and 0.5 
ng/ml IL-I[~ OD450,,m = 0.809 (S.D. = 0.189). Similar results were 
observed in two separate xperiments. 
ECV304 cells stably transfected with pGLneoVCAM-1 were plated 
in a gelatin coated Falcon 48-well tissue culture plate (Becton-Dick- 
inson, Franklin Lakes, N J) and allowed to incubate overnight. The 
cells were then treated in a similar manner as for the ELISA. Follow- 
ing the 6 h incubation, cells were washed with PBS and then lysed 
with 50 ~tl ysis buffer (0.1 M KPO4 (pH 8), 0.1% Triton X-100, 1 mM 
DTT, 2 mM EDTA). The lysed cells were then placed at -20°C 
overnight. After thawing, 5 t-tl of the lysate was added to 100 ~tl of 
luciferase assay buffer (Promega, Madison, WI) and immediately ana- 
lyzed for light production in a Monolight 2010 luminometer (Analy- 
tical Luminescence Laboratories, Sorrento Valley, CA). The amount 
of light emitted (light units) by the cell lysate was measured for 10 s. 
2. 7. Electrophoretic mobility shift assay (EMSA) 
Nuclear extracts were prepared from 5 X 106 HUVEC as described 
[21]. Protein concentrations in nuclear extracts were 1-5 mg/ml, as 
determined by BCA protein assay (Pierce, Rockford IL). An oligonu- 
cleotide containing the murine Ig~; site (underlined), 5'-CA- 
GAGGGACTTTCCGAGA-3', was obtained from Operon Technol- 
ogies, Inc. (Alameda, CA). Analysis of NF-~B protein binding was 
performed as described [21]. For competition and antibody supershift 
experiments, binding reactions were incubated with unlabeled ouble- 
stranded oligonucleotides or monospecific antibodies for 20 rain be- 
fore the addition of the radiolabeled oligonucleotide. Anti-p65, anti-c- 
Rel and anti-p50 rabbit polyclonal antibodies were purchased from 
Santa Cruz Biotechnology. 
3. Results 
Previous studies have shown that a novel series of com- 
pounds inhibited the adhesion of neutrophils to TNF-t~ stim- 
ulated endothelial cells [18]. In the present study, we investi- 
gated the effects of one of these compounds,  BZT (Fig. 1), on 
IL-I[~ induced VCAM-1 gene expression and activation of 
NF-~B in human endothelial cells. 
We first examined the inhibitory effects of BZT on IL-113 
induced cell surface expression of VCAM-1 using HUVEC.  
ELISA assays were performed and the data is presented in 
Fig. 2. BZT is much more potent in blocking the cytokine 
induced cell surface expression of VCAM-1 than TPCK,  a 
protease inhibitor that has been shown to block cytokine ac- 
t ivation of NF-~cB [14]. 
We next investigated the effects of BZT on the IL-I[3 in- 
duced upregulation of VCAM-1 mRNA in HUVEC.  As 
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Fig. 3. BZT inhibits VCAM-1 mRNA but not PAI-1 or [3-actin in 
HUVEC treated with IL-1!3. HUVEC monolayers were treated with 
10 ktM BZT or 50 ~tM TPCK for 30 min prior to the addition of 
0.5 ng/ml IL-l[3. The cells were then incubated for 6 h with the test 
compounds plus IL-l[3 and then total RNA was isolated. 1 ~tg of 
total RNA was used for RT/PCR analysis. (A) VCAM-1 specific 
primers. (B) PAl-1 specific primers. (C) 13-Actin specific primers. 
shown in Fig. 3, 10 ~tM BZT and 50 ~tM TPCK blocked the 
IL-1[3 induction of VCAM-1 mRNA. BZT and TPCK did not 
block the IL-1I~ induced upregulation of PAI-1 mRNA or the 
constitutive expression of ]3-actin mRNA (Fig. 3). 
To determine if BZT inhibited VCAM-1 promoter activity, 
ECV304 cells were stably transfected with pGLneoVCAM-1. 
ECV304 cells containing pGLneoVCAM-1 exhibited a time- 
and dose-dependent i duction of luciferase activity in re- 
sponse to IL-I~ similar to HUVEC transiently transfected 
with the same reporter gene plasmid (data not shown). There- 
fore, these cells were chosen to examine the inhibition of the 
VCAM-1 promoter activity by BZT. As shown in Fig. 4, BZT 
blocked IL-1]3 induced VCAM-1 promoter activity. Again, 
BZT was a more potent inhibitor of VCAM-1 promoter ac- 
tivity than TPCK. 
Previous tudies have shown that NF-lcB is involved in the 
induction of VCAM-1 gene expression in endothelial cells 
[4,5]. The effects of BZT on the activation of NF-~:B were 
analyzed using EMSAs. As shown in Fig. 5, BZT did not 
block IL-1]3 induced NF-~cB nuclear translocation. In con- 
trast, TPCK did block IL-I~ induced NF-~cB translocation 
to the nucleus (data not shown). The complex formed using 
this oligonucleotide containing a prototypic ~B site was char- 
acterized by competition and antibody supershift experiments. 
The complex was competed with an unlabeled oligonucleotide 
containing a wild-type ~cB site but not with an unlabeled oli- 
gonucleotide containing a mutated ~:B site (Fig. 5). In addi- 
tion, the complex was specifically supershifted by anti-p50 and 
anti-p65 antibodies but not by anti-c-Rel antibodies, indicat- 
ing that it represented binding of p50/p65 heterodimers (Fig. 
5). 
4. Discussion 
In the present study we have investigated the effects of a 
benzothiophene-carboxamide (BZT) on the IL-I[3 stimulated 
induction of VCAM-I gene expression in human endothelial 
cells. Previous tudies have shown that compounds of similar 
structure were effective in blocking neutrophil adhesion to 
TNF-c~ stimulated HUVEC [18]. Here we present evidence 
that BZT is a potent inhibitor of IL-I~ stimulated induction 
of VCAM-1 cell surface expression and VCAM-1 promoter 
activity. 
Previous reports have shown that activation of NF-~B is 
required for cytokine induced VCAM-1 gene expression [4,5]. 
In this study, EMSAs demonstrated that BZT did not inhibit 
IL-113 induced nuclear translocation of NF-~cB. Our findings 
are similar to a report by Stuhlmeir et al. [23], which demon- 
strated inhibition of cytokine induced gene expression of 
VCAM-1, ICAM-1, and E-selectin without inhibition of 
NF-~cB activation. These data indicate that NF-~cB nuclear 
translocation alone is not sufficient for IL-II3 induced upregu- 
lation of VCAM-1 in endothelial cells. 
We also examined the effects of BZT on IL-113 induced 
stimulation of PAI-1 mRNA, which is regulated by an NF- 
~cB independent mechanism [22]. BZT did not block the IL-I[3 
induction of PAI-1 mRNA in endothelial cells, indicating that 
BZT does not inhibit all IL-113 induced intracellular signaling 
cascades in human endothelial cells. 
At least two different mechanisms of action could explain 
the effects of BZT on endothelial cells. It is possible that the 
transactivating domain of the p65 subunit NF-~cB may be the 
target of the inhibition. One could envisage that nuclear trans- 
location of NF-~B is not modulated by BZT, but its ability to 
induce transcription is inhibited. Alternatively, BZT may 
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Fig. 4. Inhibition of IL-l[3 stimulated VCAM-1 promoter activity in 
endothelial cells by BZT. ECV304 cells stably transfected with 
pGLneoVCAM-1 were pre-treated with the indicated concentrations 
of BZT or TPCK for 30 min prior to addition of 0.5 ng/ml IL-I~. 
Cells were treated for 6 h with IL-113 and the compound. Cells were 
then lysed and lysates were then analyzed for luciferase activity. 
Samples were performed in triplicate and tests were performed a
minimum of three times. 
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Fig. 5. IL-I~ activation of NF-~:B in HUVEC. Nuclear extracts were prepared from unstimulated HUVEC (lane 1) and HUVEC incubated for 
1 h with 1 ng/ml IL-113 with or without a 30 min pretreatment with 10 gM BZT (lanes 2,3). The presence of NF-~:B was determined by EMSA 
using a radiolabeled oligonucleotide containing a prototype ~B site. IL-I~ stimulation of HUVEC activated NF-~B (arrow). Competition ex- 
periments were performed using 100 × molar excess of an oligonucleotide containing a wild-type ~B site (GGGACTTTCC) (lane 5) or a mu- 
tated ~B site (CGGACTTAGA) (lane 6). The protein composition of the complex was determined by antibody (Ab) supershift experiments 
using anti-p50 (lane 8), anti-p65 (lane 9) and anti-c-Rel (lane 10) antibodies. 
block the activation of other transcription factors involved in 
the IL-1 [3 stimulated induction of VCAM-1 gene expression in 
endothelial cells such as the interferon regulatory factor 1 [24]. 
Future studies will investigate the molecular target of BZT. 
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